Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the ability to delete aSMA + myofibroblasts in pancreatic cancer were generated. Depletion starting at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal transition, and cancer stem cells, with diminished animal survival. In PDAC patients, fewer myofibroblasts in their tumors also correlated with reduced survival. Suppressed immune surveillance with increased CD4 + Foxp3 + Tregs was observed in myofibroblast-depleted mouse tumors. Although myofibroblast-depleted tumors did not respond to gemcitabine, anti-CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival. This study underscores the need for caution in targeting carcinoma-associated fibroblasts in PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a near uniformly lethal disease with a dismal median survival of 4 to 6 months (Hidalgo, 2010; Korc, 2007) . Despite years of efforts to design therapeutic approaches for pancreatic cancer, the use of conventional chemotherapy combination regimens with modest benefit remains the only option for the overwhelming majority of patients who present with advanced neoplasms. Revisiting the complex biology of PDAC in an unbiased manner is thus urgently required if we are to develop more effective therapies. The progress in generating genetically engineered mouse models faithfully mimicking human PDAC provides a unique opportunity to interrogate the functional contribution of the desmoplastic
Significance
Pancreas cancer is associated with large amounts of stroma composed of collagen I and myofibroblasts, but their functional contribution remains unknown. Specific depletion of myofibroblasts using compound genetic mouse models of PDAC leads to aggressive tumors with diminished animal survival. Fewer myofibroblasts in human PDAC also correlate with reduced patient survival. Detailed studies show that myofibroblast loss decreases the ability of the immune system to control cancer associated with the persistence of regulatory T cells. Myofibroblast depletion did not improve gemcitabine's efficacy, but immunotherapy to revive immune attack prolonged mice's survival. This study demonstrates a protective role of myofibroblasts and suggests that targeting carcinoma-associated fibroblasts in pancreas cancer should be approached with caution. (legend continued on next page) stromal reaction in PDAC, a defining feature of this carcinoma, which accounts for the majority of the tumor tissue volume (Aguirre et al., 2003; Bardeesy et al., 2006a Bardeesy et al., , 2006b Gidekel Friedlander et al., 2009; Hingorani et al., 2003 Hingorani et al., , 2005 Hruban et al., 2007; Ijichi et al., 2006) . The cellular component of the desmoplastic stroma in PDAC is composed primarily of myofibroblasts, characterized by aSMA expression (Feig et al., 2012; Rasheed et al., 2012) . Recent studies have implicated the stroma as a physical barrier to the delivery of cytotoxic chemotherapies to the peritumoral milieu (Feig et al., 2012; Provenzano et al., 2012; Whatcott et al., 2012) . Nonetheless, although preclinical models have demonstrated the benefit of stromal depletion through blockade of paracrine Hedgehog signaling in accentuating drug delivery (Olive et al., 2009) , subsequent clinical trials targeting stromal myofibroblasts in human PDAC resulted in an apparent paradoxical accelerated disease progression, halting clinical trials (Amakye et al., 2013) . These studies reinforced the need to critically evaluate the functional contribution of stroma in the initiation and progression of PDAC. In this regard, the functional role of aSMA + myofibroblasts and type I collagen in PDAC remains unknown.
RESULTS

Myofibroblast Depletion Leads to Increased Tumor Invasion Associated with Decreased Survival
To interrogate the functional contribution of aSMA + myofibroblasts in PDAC, we used a genetic strategy for selective in vivo depletion. Ptf1a cre/+ ;LSL-Kras G12D/+ ;Tgfbr2 flox/flox (PKT) mice develop spontaneous PDAC with full penetrance that reliably recapitulates the clinical and histopathological features of the human disease (Ijichi et al., 2006) . The mice consistently progress from pancreatic intraepithelial neoplasia (PanIN) at 4.5 weeks of age to invasive cancer at 6 weeks of age and die at 8 weeks of age, without much variation (Ijichi et al., 2006) . These mice were crossed with aSMA-tk transgenic mice to selectively target proliferating aSMA + myofibroblasts upon systemic ganciclovir (GCV; InvivoGen) administration (PKT; aSMA-tk mice) (LeBleu et al., 2013) . Daily GCV injections were initiated when mice developed PanIN lesions (early) and allowed to progress to PDAC ( Figure 1A ). Mice also received GCV injections starting at the established PDAC stage (late) until they developed significant signs of illness leading to their death or requiring euthanasia ( Figure 1A ). In both early and late myofibroblast depletion settings, PKT mice presented with significantly more invasive, undifferentiated, and necrotic tumors when myofibroblasts were depleted compared with control tumors (Figures 1B-1E ). Immunohistochemical and immunofluorescence analyses revealed an average of 80% depletion of proliferating myofibroblasts (Figure 1F ; Figures S1A and S1B available online). Direct visualization of interstitial myofibroblasts using the aSMA-RFP transgenic mice crossed with PKT; aSMA-tk mice also showed approximately 80% depletion of total myofibroblasts ( Figure 1G ). A significant reduction in aSMA transcript level was also noted in depleted tumors ( Figure S1C ). Extrapancreatic organs, such as the kidney, lung, small bowel, heart, and liver, did not show any depletion in aSMA + cells ( Figures S1D and S1E) . Notably, myofibroblast depletion in PDAC was associated with significant reduction in survival, in both the early and late depletion groups ( Figure 1H ). Tumor weight was significantly reduced by myofibroblast depletion and was associated with a reduced body weight specifically in PDAC mice with late myofibroblast depletion (Figures S1F and S1G). Mice with myofibroblast-depleted tumors exhibit an increased frequency of pulmonary emboli, likely contributing to diminished overall survival ( Figure S1H ). Loss of one allele of Tgfbr2 (versus both in the PKT mice) in the context of Kras G12D activation (PKT Het mice) leads to a similar PDAC phenotype, but with a slower progression rate, with PanIN lesions noted at 4 to 6 weeks of age and PDAC at 8 to 10 weeks of age (Ijichi et al., 2006) . GCV treatment was initiated at the onset of PDAC in PKT Het ; aSMA-tk mice and continued until they died or were moribund, requiring euthanasia. Depletion of myofibroblasts resulted in undifferentiated tumors (Figures 2A-2E ) and significantly diminished the survival of PKT Het ; aSMA-tk mice ( Figure 2F ). Similar findings were also observed when myofibroblasts were depleted in Pdx1 cre/+ ;LSL-Kras G12D/+ ;Trp53 R172H/+ (KPC) mice crossed with aSMA-tk (KPC; aSMA-tk) mice. Myofibroblast depletion in this setting also resulted in poorly differentiated tumors and significantly diminished survival ( Figures  S2A-S2C) . Because of the similar phenotypes of the PKT; aSMA-tk mice and KPC; aSMA-tk mice, the remaining experiments were carried out using the PKT mice because of their faster course of disease. On the basis of the striking and somewhat unexpected impact of stromal depletion on survival in PDAC models, we next assessed whether a comparable impact of stromal content was observed in the cognate human setting. Immunohistochemical scoring for interstitial aSMA + cells from resected PDAC of untreated patients indicated that low aSMA is associated with (B) Representative micrographs of H&E stained pancreatic samples (scale bar represents 100 mm). (C) Pathological scores of early-depleted tumors (left: wild-type [WT], n = 5; control, n = 16; depleted, n = 17) and late-depleted tumors (right: WT, n = 5; control, n = 17; depleted, n = 26). Significance was determined by one-way ANOVA with Tukey post hoc analysis. (D) Necrosis penetrance of early-depleted tumors (left: WT, n = 5; control, n = 16; depleted, n = 22) and late-depleted tumors (right: WT, n = 5; control, n = 17; depleted, n = 25). (E) Relative percentages in histological phenotypes in late depleted tumors. Control, n = 17; depleted, n = 25. (F) Representative micrographs (scale bar represents 50 mm) of Ki-67/aSMA dual-immunofluorescence (left, control; right, depleted) and corresponding quantification (n = 4 and n = 6 for control and depleted, respectively). Arrows point to double-positive cells and inserts show high-magnification images (scale bar represents 25 mm). (G) Representative micrographs (scale bar represents 100 mm) of reporter aSMA-RFP tumor samples (left, control; right, depleted) and corresponding quantification (n = 3 in each group).
(H) Survival analysis of early (left) and late (right) treatment groups. GCV, GCV treatment was initiated. Data are represented as mean ± SEM. Unless otherwise noted, significance was determined using t tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). ns, not significant. See also Figure S1 . (B) . WT, n = 5; control, n = 6; depleted, n = 4. Significance was determined by one-way ANOVA with Tukey post hoc analysis. (C) Relative percentages in histological phenotypes (n = 6 and n = 4, respectively, for control and depleted).
(D and E) Representative micrographs of aSMA stained pancreatic samples as in (A) (D) (scale bar represents 100 mm) and corresponding quantification (E) (n = 6 and n = 4, respectively, for control and depleted). V, vessel.
(F) Survival analysis in PKT Het mice. GCV, GCV treatment was initiated.
(G) Representative micrographs of aSMA stained pancreatic samples resected from patients in each score category: 0, 1, 2, and 3 (scale bar represents 200 mm).
(H) Survival analysis based on histopathological score (left) and aSMA score (right). Low aSMA: scores 0 and 1; high aSMA: scores 2 and 3. Significance was determined using the Mantel-Cox test. Data are represented as mean ± SEM. Unless otherwise noted, significance was determined using t tests (*p < 0.05, ***p < 0.001, ****p < 0.0001). ns, not significant. See also Figure S2 and Table S1 .
worse survival, supporting the observations in the PKT and KPC mice with myofibroblast depletion ( Figure 2G ; Table S1 ). Of note, patients with low aSMA scores present significantly more often with poorly differentiated cancers than tumors with well or moderate differentiation (Table S1) , and yet despite this correlation, aSMA scoring offered greater significance in differential stratification of patients for survival than histopathological grade (Figure 2H ), suggesting that stromal content likely has a direct impact on the natural history of human PDAC. Figures S3A-S3D ). Tumor collagen content assayed by type I collagen immunostaining ( Figure 3A ) was significantly decreased in myofibroblastdepleted tumors. Masson's trichrome staining (MTS) and picrosirius red staining revealed a significant reorganization of collagen fibrils, with decreased stiffness and elastic modulus in myofibroblast-depleted tumors compared with control tumors ( Figures 3B-3D ). Interestingly, collagen crosslinking and immunolabeling for the collagen crosslinking enzyme lysyl oxidase (LOX) were unchanged despite reduced stiffness of the ECM ( Figures 3E and 3F ), highlighting a complex regulation of type I collagen crosslinking mediated by multiple sources of LOX. These results are consistent with the ability of aSMA + myofibroblasts to produce type I collagen and induce fibrosis in PDAC. Despite extensive remodeling of type I collagen ECM in myofibroblast-depleted tumors, hyaluronic acid (HA) binding protein (HABP), a marker for total HA content, remained unchanged in the myofibroblast-depleted tumors ( Figure S3E ). Vimentin labeling, however, was significantly decreased in myofibroblastdepleted tumors ( Figure S3F ). Auditing of other mesenchymal cells in the PDAC tumor stroma revealed a decrease in the number of fibroblast-specific protein 1 (FSP1)/S100A4 + cells in myofibroblast-depleted tumors ( Figure S3G ), while the number of fibroblast activation protein (FAP)-positive cells remained unchanged ( Figure S3H ). Colocalization of aSMA with FAP was not detectable in the PDAC tumors ( Figure S3H ).
Myofibroblast
Myofibroblast-Depleted PDAC Displays Suppression of Angiogenesis, Enhanced Tumor Hypoxia, EMT Program, and Cancer Stem Cell-like Phenotype Histopathological analyses of myofibroblast-depleted tumors revealed highly undifferentiated, invasive-grade tumors with enhanced necrosis (Figures 1B-1E ). These features are associated with tumor hypoxia and the acquisition of an EMT program. Myofibroblast depletion was associated with a decrease in the number of CD31 + vessels, indicative of suppressed vessel density ( Figure 4A ; Figures S4A-S4C ). Perivascular aSMA + cells appear unaffected by the aSMA-tk strategy ( Figure S4A ). Global gene expression profiling performed on normal pancreas fibroblasts and PDAC-associated fibroblasts (CAF) shows differences in pathways affecting ECM remodeling, angiogenesis, and immune response in PDAC ( Figure S4D ; Table S3 ). RNA sequencing analyses further validated the increased expression of several proangiogenic factors in CAF, supporting their proangiogenic role in PDAC (Table S3) .
Although pericyte numbers, assayed by immunostaining analyses for the pericyte marker NG2 ( Figure S4B ), and vascular leakage, determined by extravascular fluorescein isothiocyanate (FITC)-dextran ( Figure 4B ; Figure S4E ), were unchanged, tumor hypoxia assayed by staining for pimonidazole adduct formation was dramatically increased in myofibroblast-depleted tumors compared with control tumors ( Figure 4C ; Figure S4F ). Figure 4D ; Figure S4G ) and enhanced expression of the EMT transcriptional regulators, Twist, Snail, and Slug ( Figure 4E ). The enhanced acquisition of EMT was associated with the loss of mucin staining ( Figure S4H ), which is in alignment with the decreased histological differentiation within the neoplastic glands ( Figures 1B-1E ). YFP + cancer cells from myofibroblast-depleted tumors exhibited an increase in their capacity to form spheres in culture, a feature of cells with EMT program and potential cancer stem cell-like phenotype (Kalluri and Weinberg, 2009; Scheel and Weinberg, 2012) (Figure 4F ; Figure S4I ). Additionally, the number of CD44 + CD133 + cells (suggestive of pancreatic cancer stem cells; Hermann et al., 2007; Simeone, 2008) was enhanced in myofibroblastdepleted tumors ( Figure 4G ). Fluorescence-activated cell sorted YFP + cells freshly isolated from myofibroblast-depleted tumors showed enhanced tumorigenic potential when implanted in nude mice ( Figure 4H ). Interestingly, cancer cells with EMT program and expression of aSMA were not eliminated in the PKT; aSMA-tk mice on GCV administration but increased in number ( Figure 4D ). This could be explained by the observation that cancer cells with EMT program likely do not proliferate (Tsai et al., 2012; Vega et al., 2004) , further confirming their low-cyclingstem-cell status. Further, although overall apoptosis was significantly increased in myofibroblast-depleted tumors (Figures S4J and S4K) , it was mostly localized within terminally differentiated compartments, such as islets ( Figure S4K ).
Reduction of Fibrosis Does Not Increase the Efficacy of Gemcitabine in PDAC
To test whether the decrease in myofibroblasts and type I collagen content along with reduced ECM stiffness leads to increased efficacy of gemcitabine (GEM), we treated control and myofibroblast-depleted mice with GEM. Histopathological score did not improve when PKT mice were treated with GEM alone or in combination with myofibroblast depletion ( Figure 5A ). TUNEL + cell number increased with myofibroblast depletion, independent of GEM treatment, and GEM treatment alone did not significantly increase tumor cell apoptosis ( Figure 5B ). Similarly,
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Myofibroblasts in PDAC Data are represented as mean ± SEM. Significance was determined using t tests (*p < 0.05, ***p < 0.001). ns, not significant. See also Figure S3 and Table S2 .
Myofibroblasts in PDAC the change in FSP1 + cells correlated only with myofibroblast depletion and was independent of GEM treatment ( Figure 5C ). Interestingly, CD31
+ cell numbers decreased with GEM therapy and decreased further with myofibroblast depletion ( Figure 5D ).
Standard uptake values computed from 18 F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) revealed comparable glycolysis per tumor volume in control, depleted, and GEM therapy in depleted tumors ( Figure 5E ). Despite a robust decrease in collagen content associated with myofibroblast depletion (fibrosis) ( Figure 5F ), GEM therapy did not improve overall survival ( Figure 5G ). Further, GEM therapy of PDAC compared with untreated mice did not result in improved survival, as previously reported using a different PDAC mouse model (Olive et al., 2009 ) ( Figure 5G ). GEM therapy in myofibroblast-depleted tumors compared with myofibroblast-depleted tumors also failed to improve overall survival ( Figure 5G ).
Myofibroblast Depletion Decreases Overall Immune Infiltration in PDAC but Results in Increased Frequency of FoxP3 + Treg Cells
Gene expression profiling and RNA sequence analyses comparing control tumors with myofibroblast-depleted tumors revealed a significant change in the expression of genes associated with tumor immunity, including those associated with acute inflammatory responses, regulation of macrophage activation, regulation of T cell-mediated cytotoxicity, antigen presentation, and B cell activation ( Figure 6A ; Table S2 ). Tumors with myofibroblast depletion starting at the PanIN stage (early) present with significant decreases in overall peritumoral infiltration of CD45 + cells and CD3 + T cell and CD19 + B cell infiltration compared with control tumors ( Figure S5A ). Such reductions in T cells and B cells were not observed in established PDAC with myofibroblast depletion (late-stage depletion) ( Figure S5A ). Natural killer (NK) cell infiltration with myofibroblast depletion was unchanged following myofibroblast depletion ( Figure S5A ). In both early and late depletion settings, myofibroblast depletion was associated with a significant suppression in the percentage of effector T cells (Teff, CD4 + Foxp3 À ) together with an increase in the percentage of regulator T cells (Treg, CD4 + Foxp3 + ), leading to an overall decrease in the Teff/Treg ratio ( Figures 6B-6D ). Myofibroblast depletion resulted in increased Foxp3 and Ctla4 expression assayed by immunohistochemistry (IHC) ( Figure S5B ) and real-time PCR analysis ( Figure 6E ), respectively, consistent with the enhanced Treg infiltration. The cytotoxic CD8 + /Treg ratio was also decreased in the myofibroblast-depleted tumor ( Figure 6F ), as well as CD3 + /CD11b + ratio (early depletion; Figure 6G ). The percentages of Teff and Treg, respectively, correlate with disease progression and acceleration of PDAC associated with myofibroblast depletion (Figures 6H and 6I ). Figures 6J and 6K ), whereas the percentage of macrophages (CD11b + Gr1 À F4/80 + ) was suppressed ( Figure 6L ). The differential tumor immune infiltration in early versus late depletion is also substantiated by distinct expression patterns in respective tumor immune gene expression signature, with a selectively downregulated tumor immunity gene signature in late-depleted tumor ( Figure 6A ).
Anti-CTLA-4 Antibody Therapy Rescues Enhanced PDAC Progression upon Myofibroblast Depletion and Increases Overall Survival
Myofibroblast depletion starting at early-and late-stage tumors resulted in a decreased Teff/Treg ratio associated with increased CTLA-4 expression ( Figures 6D and 6E ). Therefore, we tested whether the Teff/Treg ratio in PDAC mice with myofibroblast depletion can be rescued by CTLA-4 checkpoint blockade. Anti-CLTA-4 antibody administration significantly improved histopathological scores associated with a reduction in undifferentiated cancer cells ( Figure 7A ). Despite similar myofibroblast depletion ( Figure 7B ), suggesting that anti-CTLA-4 per se did not alter myofibroblast number, anti-CTLA-4 antibody treatment induced tumor clearance and replacement by normal parenchyma in up to 25% of the organ ( Figure 7C ). Treatment with anti-CTLA-4 antibodies in the setting of stromal depletion not only resulted in a rescue of the phenotype of myofibroblastdepleted tumors but also attenuated PDAC progression, which was associated with a significant extension in overall survival (an average increase of 60% in lifespan) ( Figure 7D ). Such elongation of lifespan was associated with reduced frequency of pulmonary emboli ( Figure 7E ). This was noticed in concordance with restored Teff and Treg percentages ( Figure 7F ) and diminished tumor sphere-forming ability within remnant cancer cells in age-matched mice ( Figure 7G ). Further, the transcriptome of myofibroblast-depleted tumors treated with anti-CTLA-4 clustered with the expression profiles of control tumor rather than myofibroblast-depleted tumors, suggesting that transcriptional reprogramming accompanies the observed phenotypic rescue (clustering using the 2,344 differentially expressed genes in late-depleted tumors versus control) ( Figure 7H ). Anti-CTLA-4 alone did not alter aSMA + content, and histopathological analyses revealed a modest increase in the percentage of normal parenchyma ( Figures S6A and S6B ). Treatment with anti-CTLA-4 alone improved overall survival (median survival of 49.5 days, compared with 47 days in the control group), albeit to a much lesser extent than anti-CTLA-4 treatment in combination with fibrosis depletion (median survival of 65 days) ( Figure 7D ).
DISCUSSION
The desmoplastic reaction is thought to represent a host defense mechanism, similar to wound healing and tissue regeneration, to repair or hopefully impede the conversion of a neoplastic lesion into invasive carcinoma (Bissell and Radisky, 2001; Dvorak, 1986; Lu et al., 2012) . The function of desmoplastic stroma is likely dynamic during cancer progression, and its heterogeneous cellular and noncellular constituents change in relation to the evolving genetic landscape of cancer cells. In this regard, several studies have suggested that aSMA + myofibroblasts and type I collagen associated with tumor fibrosis are tumor promoting in solid tumors, including PDAC (Angeli et al., 2009; Karnoub et al., 2007; Merika et al., 2012; Vong and Kalluri, 2011) . We demonstrate that depletion of aSMA + myofibroblasts resulted in multiple adverse outcomes leading to poor survival. These results suggest that at both early and late stages of pancreatic cancer, fibrosis associated with myofibroblasts and type I collagen constitutes a protective response from the host rather than offering an oncogenic supportive role, as speculated (Armstrong et al., 2004; Omary et al., 2007 ). This conclusion is supported by the clinical correlation between high aSMA and improved survival; a similar trend was previously reported from analyses also performed on resected tumors from treatmentnaive patients (Wang et al., 2013) . Although other studies have also attempted to specifically address the correlation between relative tumor content in aSMA + myofibroblasts and PDAC patient outcomes, potential therapeutic intervention prior to tumor resection makes interpretations unclear (Erkan et al., 2008; Mani et al., 2008) .
Myofibroblast depletion leads to extensive remodeling of the tumor ECM, with a significant decrease in tumor tissue stiffness and total collagen content. Myofibroblasts contribute to the production of type I collagen, albeit likely not all of it. Contrary to previous assumptions, myofibroblasts do not contribute to the total production of LOX, an enzyme responsible for crosslinking of type I collagen. In this regard, we did not observe a difference in crosslinking, despite significant depletion and reorganization of tumor-associated collagen. Therefore, cancer cells or other stromal cells may compensate LOX expression. Similar to LOX, myofibroblast depletion did not affect HA content of the tumors, suggesting a nonmyofibroblast source for this matrix molecule. Targeting HA using PEGPH20, a modified enzyme that degrades HA, yielded promising results when combined with GEM (Jacobetz et al., 2013; Provenzano et al., 2012) . In our study, ECM remodeling and the significant reduction in collagen content via myofibroblast depletion did not improve the treatment efficacy of GEM. Therefore, PDAC-associated myofibroblasts and type I collagen do not appear to serve as physical barriers to the exposure of cancer cells to GEM. In this regard, the potential role of HA, independent of type I collagen, in determining interstitial fluid pressure in PDAC tissue needs further mechanistic unraveling, and clinical trials with PEGPH20 will offer more insights in the future (Provenzano et al., 2012) .
As noted above, significant depletion of myofibroblasts and type I collagen did not alter vessel permeability and perfusion. GEM efficacy was unaltered in myofibroblast and type I collagen-depleted tumors, suggesting that the increased efficacy observed in preclinical models treated with GEM and Smoothened inhibitor IPI-926 was likely due to mechanisms independent of myofibroblasts and type I collagen (Olive et al., 2009 ). It is likely that Smoothened inhibition was not myofibroblast specific and could also have affected other stromal cells, such as endothelial cells. In this regard, further analysis of the failed clinical trials could shed further light on this matter (Amakye et al., 2013) . It is possible that if higher doses of IPI-926 combined with prolonged treatment period were used in the preclinical setting, potential adverse effects may have been encountered (Olive et al., 2009; Amakye et al., 2013) . Nevertheless, our direct approach of targeting myofibroblasts and the associated fibrosis offers further insights into the complexity of using pharmacological targeting to derive specific answers related to target cells in tumors (Olive et al., 2009 ).
An interesting corollary that emerges from this study is the dominant contribution of cell division in the accumulation of myofibroblasts in PDAC. The origin of myofibroblasts in PDAC may be diverse (Phillips, 2012; Scarlett et al., 2011 ), yet using the aSMA-tk strategy to ablate proliferating myofibroblasts, we show 80% depletion of these cells, which account for the majority of myofibroblasts in PDAC tumors. These results offer an opportunity to speculate that drugs such as GEM and paclitaxel, which target proliferating cancer cells, may also target proliferating myofibroblasts. Such dual targeting may likely compromise the efficacy of GEM over time, because of progressive depletion of protective fibrosis along with proliferating cancer cells, resulting in the eventual emergence of resistant cancer cells with EMT program and stem cell-like phenotype.
Intratumoral hypoxia was dramatically increased in myofibroblast-depleted tumors. Decreased tumor vasculature, despite intact vessel structural integrity and permeability status, may have directly contributed to the increased tumor hypoxia when myofibroblasts are depleted, consequently promoting enhanced invasiveness and an undifferentiated phenotype of cancer cells (Cheresh and Stupack, 2008; Cooke et al., 2012; Pà ez-Ribes et al., 2009) . Impaired paracrine signaling between myofibroblasts and cancer cells and alteration of ECM microenvironment due to myofibroblast depletion might also have directly contributed to changes in cancer cells, lending to the acquisition of EMT program, stem cell-like phenotype, and an undifferentiated state. Many studies have indeed suggested that altered matrix microenvironment can influence the acquisition of epigenetic changes in epithelial cells (Bissell et al., 2005; Grassian et al., 2011; Guerra et al., 2011) . Data are represented as mean ± SEM. Unless otherwise noted, significance was determined using t tests (*p < 0.05, **p < 0.01, ****p < 0.0001). ns, not significant. See also Figure S4 and Table S3 . Cancer Cell
Myofibroblasts in PDAC
The most dramatic impact of myofibroblast depletion was on the composition of the immune infiltrate in the tumor microenvironment. The interplay between cancer-associated fibroblasts and immune cells has long been recognized as a major contributor of cancer development (Coussens and Werb, 2002; Erez et al., 2010; Kalluri and Zeisberg, 2006) . Here, we demonstrate that the immune response (innate and adaptive) associated with PDAC tumors was significantly impaired when fibrosis was reduced starting at the PanIN stage or at the PDAC stage. Myofibroblast-depleted tumors are associated with a decreased Teff/Treg ratio and a significant elevation in Ctla4 expression. Myofibroblast depletion coupled with inhibition of checkpoint blockade using anti-CTLA-4 antibodies significantly ameliorated tumor burden in mice with established PDAC and improved overall survival. Our data suggest that although myofibroblast depletion results in the suppression of immune surveillance, an opportunist immune profile dominated by suppressor T cells emerges in the tumor, offering a viable checkpoint blockade target using anti-CTLA-4 antibodies. Although this antibody shows marginal efficacy in control PDAC mice with normal levels of fibrosis, depletion of fibrosis unravels more robust efficacy, likely because of significant changes in the microenvironment. Small proof-of-concept trials with ipilimumab have revealed some anecdotal responses (Royal et al., 2010) , and our study suggests that stratifying patients on the basis of their fibrosis scores might offer better responses. This is supported by the fact that ipilimumab showed dramatic efficacy in metastatic melanoma (Robert et al., 2011) , a cancer with low levels of overall stroma.
In summary, our study, together with other ongoing efforts to elucidate pancreatic tumor immunity and immunotherapy (Bayne et al., 2012; Clark et al., 2007; Hiraoka et al., 2006; Roberts et al., 2013; Vonderheide et al., 2013) , will likely offer insights into potential efficacy of combination therapies involving immunotherapy in patients with pancreas cancer.
EXPERIMENTAL PROCEDURES
Animal Studies
The disease progression and genotyping for the PKT mice was previously described (Ijichi et al., 2006) . PKT mice were crossed to R26-LSL-EYFP (purchased from Jackson Laboratory), aSMA-tk (LeBleu et al., 2013) , and aSMA-RFP (LeBleu et al., 2013) mice. Mice received daily intraperitoneal (i.p.) injections with 50 mg/kg body weight of GCV at 4 to 4.5 weeks of age (30.3 ± 1.7 days) for 14 days or less (early depletion) or at 6 weeks of age (40.7 ± 1.7 days) for 10 days or less (late depletion). One hour prior to sacrifice, mice were injected i.p. with 60 mg/kg body weight pimonidazole (Hypoxyprobe). KPC mice were previously described (Hingorani et al., 2005) and crossed to aSMA-tk mice. KPC mice were treated with GCV starting at 7 weeks of age (49 ± 2.5 days). GEM (50 mg/kg body weight; LC Laboratories) was given i.p. at day 1 and day 7, either alone or in combination with GCV. An initial 200 mg anti-CTLA-4 (BioXCell, clone 9H10, BE0131) antibody or 200 mg hamster immunoglobulin G (IgG) (BioXCell, BE0091) in 200 ml PBS was administered i.p., followed by two injections of 100 mg anti-CTLA-4 or 100 mg hamster IgG in 100 ml PBS every other day. All mice were housed under standard housing conditions at the Beth Israel Deaconess Medical Center (BIDMC) and MD Anderson Cancer Center (MDACC) animal facilities, and all animal procedures were reviewed and approved by the BIDMC and the MDACC institutional animal care and use committees. Acquisition and analysis of 18 F-FDG PET/ CT in mice is detailed in Supplemental Experimental Procedures.
Histology and Histopathology
Formalin-fixed tumors were submitted to the BIDMC and MDACC histology core facilities, and paraffin-embedded sections were cut for hematoxylin and eosin (H&E) staining and MTS. For histopathological scoring, H&E-stained slides were scored for the penetrance of each histological hallmark on a scale of 0 to 3. The predominant tumor phenotype gave the pathological score for the whole tumor (1 = well differentiated, 2 = moderately differentiated, 3 = poorly differentiated). Necrosis was also scored on a scale of 0 to 3. Lung emboli were counted in one H&E lung section per mouse evaluated. Picrosirius red staining for collagen was achieved using 0.1% picrosirius red (Direct Red 80; Sigma) and counterstained with Weigert's hematoxylin. Mucin staining was achieved using mucicarmine and metalin yellow and counter-stained with Weigert's hematoxylin.
IHC
Harvested tumors were formalin fixed prior to paraffin embedding. Sections 4 to 5 mm thick were deparaffinized, rehydrated, and boiled for 1 hr in 10 mM citrate buffer at pH 6.0. Staining for aSMA was processed using the M.O.M. Kit Tumor Spheres and Limiting Dilution Tumor Formation Assay Tumors were digested as described above, and cell suspension was filtered through a 100 mm mesh. Two million cells were plated in a low-adherence dish with 1% fetal bovine serum, Dulbecco's modified Eagle's medium, and penicillin/streptomycin/amphotericin. Three to 4 weeks later, the formed spheres were counted at 2003 magnification. For the limiting dilution assay, flow cytometry purified YFP + cancer cells (from PKT mice crossed to R26-stop-EYFP reporter mice) were pelleted and resuspended in PBS prior to subcutaneous injection in nude mice. Six nude mice received injections of YFP + cells (100, 1,000 or 10,000 cells) from tumors of PKT mice without myofibroblast depletion (control; two donor mice were used) or with myofibroblast depletion (depleted; two donor mice were used).
Gene Expression Profiling
Total RNA was isolated from tumors of PKT control mice (n = 3 at early stage, n = 3 at late stage) and myofibroblast-depleted mice (n = 4 at early stage, n = 3 at late stage, n = 2 at late stage and treated with anti-CTLA4) using RNeasy Plus Mini Kit (Qiagen) and submitted to the Microarray Core Facility at MD Anderson Cancer Center. Gene expression analysis was performed using Mouse Ref6 Gene Expression BeadChip (Illumina), and the Limma package from R Bioconductor (Carey et al., 2005) was used to analyze differentially expressed genes of myofibroblast-depleted mice versus control mice (p % 0.05, fold change R 1.5). Gene ontology and pathway analyses of differentially expressed genes are performed using the Web-accessible program Database for Annotation, Visualization and Integrated Discovery (Huang et al., 2009) .
Pathways that enrich differentially expressed genes are selected (p < 0.05). For RNA sequencing analyses, sequencing of the whole transcriptome was performed using the SOLiD system. Lifescope Genomic Analysis Software version 2.5.1 was used to map the raw data to the mouse genome (build mm10) and to quantify the counts per gene. The count data were used to perform differential expression analysis using the R package, DEseq. Quantitative real-time PCR analyses are detailed in Supplemental Experimental Procedures.
Vascular Leakage
Vascular leakage was assayed and quantified as previously described (Cooke et al., 2012) . Quantification was performed using a grading system ranging from 0 to 5, representing 0% to 100% extravascular FITC-dextran. Results were plotted as scores.
Clinical Studies
Resected tumors were obtained from 53 patients (Table S1 ) with invasive pancreatic adenocarcinoma who underwent surgical resection at Johns Hopkins Hospital after approval by the Johns Hopkins Hospital institutional review board (IRB). The cases were obtained under an IRB-exempt protocol. Clinical information was obtained from the electronic medical records. Tissue sections from paraffin-embedded specimens were stained for aSMA (Sigma) as described above, and staining intensity was scored blinded. Each tissue section was surveyed entirely for aSMA stain intensity in interstitial fibroblasts. aSMA + vessels of all sizes were easily distinguishable from interstitial fibroblasts. Overall, few aSMA + vessels were detected in the tumors, and these were not included in the score. A scale of 0 to 3 was used (0 = no detected staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining). Patients were then divided into two groups: a ''low aSMA'' group, as defined by scores of 0 and 1, and a ''high aSMA'' group, as defined by scores of 2 and 3. KaplanMeier plots were drawn for each group and statistical differences evaluated using the log rank Mantel-Cox test.
Statistics
Statistical analyses of pathological scores, flow cytometry, and immunohistochemical quantifications were performed by using Student's t test, one-way ANOVA, or Fisher's exact test with GraphPad Prism (GraphPad Software). Limiting dilution assay was evaluated using SPSS (SPSS) with chi-square tests. For survival analyses, Kaplan-Meier plots were drawn and statistical differences evaluated using the log rank Mantel-Cox test. A p value < 0.05 was considered statistically significant.
ACCESSION NUMBERS
The microarray data are deposited at Gene Expression Omnibus under accession numbers GSE52812 (gene expression changes comparing pancreas tumors from PKT mice with pancreas tumors from PKT; aSMA-tk mice) and GSE55871 (gene expression changes comparing myofibroblasts from pancreas tumors of PKT mice with myofibroblasts from pancreas tumors of PKT; aSMA-tk mice). Data are represented as mean ± SEM. Significance was determined using t tests, except for multiple-group comparisons, for which significance was determined using one-way ANOVA with Tukey post hoc analysis (*p < 0.05, **p < 0.01, **p < 0.001, ****p < 0.0001). ns, not significant. See also Figure S5 . 
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